MarketFlmodafinil
Company Profile

Flmodafinil

Flmodafinil, also known as bisfluoromodafinil and lauflumide, is a wakefulness-promoting agent related to modafinil which has been developed for treatment of a variety of different medical conditions. These include chronic fatigue syndrome, idiopathic hypersomnia, narcolepsy, attention deficit hyperactivity disorder (ADHD), and Alzheimer's disease. Aside from its development as a potential pharmaceutical drug, flmodafinil is sold online and used non-medically as a nootropic.

Pharmacology
Pharmacodynamics Flmodafinil is a selective dopamine reuptake inhibitor (DRI). Its affinity (Ki) for the DAT is 4,090nM. In a study comparing the wake-promoting effects of flmodafinil and modafinil, flmodafinil was found to maintain wakefulness over a significantly longer timeframe than modafinil. ==Chemistry==
Chemistry
Flmodafinil is a racemic mixture of (S)-(+)- and (R)-(–)-enantiomers. The (S)-(+) enantiomer has been referred to as JBG1-048 and the (R)-(–) enantiomer has been referred to as JBG1-049. Analogues Analogues of flmodafinil include modafinil, armodafinil ((R)-modafinil), esmodafinil ((S)-modafinil), adrafinil (CRL-40,028; N-hydroxymodafinil), fladrafinil (CRL-40,941; bisfluoroadrafinil), and CE-123, among others. ==History==
History
Flmodafinil was patented in 2013, and preclinical research has been underway since December 2015. It appears to have first been patented in the 1980s. ==See also==
tickerdossier.comtickerdossier.substack.com